CN111315751B - 葡萄糖敏感性白蛋白结合衍生物 - Google Patents

葡萄糖敏感性白蛋白结合衍生物 Download PDF

Info

Publication number
CN111315751B
CN111315751B CN201880072571.2A CN201880072571A CN111315751B CN 111315751 B CN111315751 B CN 111315751B CN 201880072571 A CN201880072571 A CN 201880072571A CN 111315751 B CN111315751 B CN 111315751B
Authority
CN
China
Prior art keywords
cooh
formula
hydroxy
nhch
dihydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880072571.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111315751A (zh
Inventor
T·克鲁瑟
M·K·汉森
M·W·B·蒙策尔
H·萨格森
P·索尔伯格
J·E·拉斯马森
C·贝伦斯
T·霍格·詹森
V·巴尔散克
Z·德罗布纳科瓦
L·德罗兹
M·阿夫拉内克
V·科特卡
M·施坦格尔
I·斯纳德尔
H·瓦纳瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to CN202311566982.6A priority Critical patent/CN117624207A/zh
Publication of CN111315751A publication Critical patent/CN111315751A/zh
Application granted granted Critical
Publication of CN111315751B publication Critical patent/CN111315751B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q3/00—Condition responsive control processes
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/10—Methods of screening libraries by measuring physical properties, e.g. mass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/088—Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880072571.2A 2017-11-09 2018-11-08 葡萄糖敏感性白蛋白结合衍生物 Active CN111315751B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311566982.6A CN117624207A (zh) 2017-11-09 2018-11-08 葡萄糖敏感性白蛋白结合衍生物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17200734 2017-11-09
EP17200734.6 2017-11-09
EP18178294 2018-06-18
EP18178294.7 2018-06-18
PCT/EP2018/080650 WO2019092125A1 (en) 2017-11-09 2018-11-08 Glucose-sensitive albumin-binding derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311566982.6A Division CN117624207A (zh) 2017-11-09 2018-11-08 葡萄糖敏感性白蛋白结合衍生物

Publications (2)

Publication Number Publication Date
CN111315751A CN111315751A (zh) 2020-06-19
CN111315751B true CN111315751B (zh) 2023-12-12

Family

ID=64049277

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880072571.2A Active CN111315751B (zh) 2017-11-09 2018-11-08 葡萄糖敏感性白蛋白结合衍生物
CN202311566982.6A Pending CN117624207A (zh) 2017-11-09 2018-11-08 葡萄糖敏感性白蛋白结合衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311566982.6A Pending CN117624207A (zh) 2017-11-09 2018-11-08 葡萄糖敏感性白蛋白结合衍生物

Country Status (7)

Country Link
US (4) US11186595B2 (https=)
EP (2) EP4227313B1 (https=)
JP (3) JP7254792B2 (https=)
CN (2) CN111315751B (https=)
ES (2) ES3056386T3 (https=)
MA (2) MA71363A (https=)
WO (1) WO2019092125A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179568A1 (en) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
WO2019092125A1 (en) * 2017-11-09 2019-05-16 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
EP3946363A2 (en) * 2019-03-29 2022-02-09 Novo Nordisk A/S Glucose sensitive insulin derivatives
CN112174989B (zh) * 2019-07-02 2023-06-20 江西同和药业股份有限公司 一种克立硼罗的制备方法
JP7834341B2 (ja) * 2019-07-31 2026-03-24 シーエス ファーマシューティカルズ エルエルシー グルコース調節型立体配座スイッチを有するインスリン類似体
EP4126058A1 (en) * 2020-03-31 2023-02-08 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
JP2024500284A (ja) * 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
EP4255468A4 (en) * 2020-12-02 2024-06-05 The Regents of University of California INJECTABLE BIODEGRADABLE POLYMER COMPLEX FOR GLUCOSE-DEPENDENT INSULIN DELIVERY
WO2022235691A1 (en) * 2021-05-03 2022-11-10 The Trustees Of Indiana University Molecular design of glucose sensors in glucose-responsive insulin analogues
CN114478597B (zh) * 2021-12-29 2023-08-29 宁波大学 一种快速识别葡萄糖手性的试剂及其制备方法和应用
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
AU2024251658A1 (en) * 2023-04-11 2025-09-18 Protomer Technologies, Inc. Compounds containing one or more diboronates and related insulin analogs
AU2024295902A1 (en) 2023-07-18 2026-01-15 Novo Nordisk A/S Pharmaceutical compositions of insulin derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008052314A1 (de) * 2008-10-15 2010-04-22 Syntatec Chemicals Gmbh Aromatische und heteroaromatische Poly-trifluoroborate und Verfahren zur Herstellung

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU628674B2 (en) 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
AU2001263775A1 (en) 2000-06-02 2001-12-11 Novo-Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
US7316999B2 (en) * 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
WO2011000823A1 (en) 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives
TWI458732B (zh) * 2012-06-27 2014-11-01 國立交通大學 具硼酸基團連接子及含有其之生物感測元件
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
WO2015097276A1 (en) * 2013-12-23 2015-07-02 Syngenta Participations Ag Benzoxaborole fungicides
WO2015106292A1 (en) * 2014-01-13 2015-07-16 Coferon, Inc. Bcr-abl tyrosine-kinase ligands capable of dimerizing in an aqueous solution, and methods of using same
AR103397A1 (es) * 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
JP6914844B2 (ja) 2015-03-13 2021-08-04 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ グルコース制御立体配座スイッチを含むインスリン類似体
WO2016179568A1 (en) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
UA121354C2 (uk) * 2016-05-12 2020-05-12 Анакор Фармасутікалз, Інк. Нові сполуки для лікування паразитарних захворювань
US10690675B2 (en) * 2017-04-14 2020-06-23 Georgia Tech Research Corporation Methods for enriching glycopeptides for global analysis of glycoproteins
WO2019092125A1 (en) * 2017-11-09 2019-05-16 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
EP3781147A4 (en) 2018-04-16 2022-04-20 University of Utah Research Foundation Glucose-responsive insulin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008052314A1 (de) * 2008-10-15 2010-04-22 Syntatec Chemicals Gmbh Aromatische und heteroaromatische Poly-trifluoroborate und Verfahren zur Herstellung

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Glucose- and pH-responsive nanogated ensemble based on polymeric network capped Mesoporous silica;Tan, Lei et al.;《ACS Applied Materials & Interfaces》;20151231;第6310-6316页 *
Preparation and screening of diboronate arrays for identification of carbohydrate binders;Hoeg-Jensen, Thomas et al.;《QSAR & Combinatorial Science》;20041231;第344-351页 *

Also Published As

Publication number Publication date
EP4227313C0 (en) 2025-10-22
US20220081451A1 (en) 2022-03-17
US11186595B2 (en) 2021-11-30
EP3707145A1 (en) 2020-09-16
JP2021502372A (ja) 2021-01-28
EP4227313A1 (en) 2023-08-16
CN117624207A (zh) 2024-03-01
MA50552A (fr) 2020-09-16
ES3056386T3 (en) 2026-02-20
JP7254792B2 (ja) 2023-04-10
US20230331745A1 (en) 2023-10-19
CN111315751A (zh) 2020-06-19
US20250122226A1 (en) 2025-04-17
US20200325160A1 (en) 2020-10-15
US11767332B2 (en) 2023-09-26
JP2023080126A (ja) 2023-06-08
EP4227313B1 (en) 2025-10-22
EP3707145B1 (en) 2023-06-21
US12227528B2 (en) 2025-02-18
ES2956032T3 (es) 2023-12-12
JP2025061325A (ja) 2025-04-10
EP3707145C0 (en) 2023-06-21
MA71363A (fr) 2025-04-30
JP7622123B2 (ja) 2025-01-27
WO2019092125A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
CN111315751B (zh) 葡萄糖敏感性白蛋白结合衍生物
TW202434275A (zh) 含有相對於ｈｒａｓ與ｎｒａｓ具有選擇性ｋｒａｓ抑制作用之環狀化合物的醫藥組成物
CN114984003B (zh) 芳族磺酰胺衍生物
CN108602806B (zh) 改进的爱帕琳肽受体(apj)激动剂及其用途
TW202309064A (zh) 環狀胜肽化合物的醫藥用途
CN106257976B (zh) 人类血浆激肽释放酶抑制剂
TW202432170A (zh) 相對於ｈｒａｓ及ｎｒａｓ具有選擇性之ｋｒａｓ抑制作用的環狀化合物
CN113164763A (zh) Nlrp3抑制剂
WO2020135771A1 (zh) 杂环类化合物、中间体、其制备方法及应用
CN113646329A (zh) 葡萄糖敏感性胰岛素衍生物
CN109715632B (zh) 大环吲哚衍生物
CN109195965A (zh) Wdr5蛋白质-蛋白质结合的抑制剂
CN113292539A (zh) 取代的氧代吡啶衍生物
TW201922721A (zh) 化學化合物
TW201429947A (zh) 昇糖素受體調節劑
TW201620887A (zh) 化合物及方法
CN116217554B (zh) 芳香类化合物、其药物组合物及其应用
WO2024169773A1 (zh) 吲唑啉酮类化合物及其制备方法和用途
CN107108638A (zh) 哌啶基吡唑并嘧啶酮及其用途
EP2470514B1 (fr) Pseudo-dipeptides comme inhibiteurs de mmp
TW202547546A (zh) 用以改善腦功能之環狀肽衍生物組成物
TW202545557A (zh) 用以調節睪固酮之產生／分泌的環狀肽衍生物組成物
WO2026055841A1 (zh) 芳环并杂环类化合物、其制备方法和其应用
WO2022052926A1 (zh) 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用
HK40005106B (zh) 大环吲哚衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Tanba

Applicant after: NOVO NORDISK A/S

Address before: Tanba

Applicant before: NOVO NORDISK A/S

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant